AI Financial Intelligence
Professional analysis of central bank decisions

Markets

News
Forex
Stocks
Crypto
Gold
Commodities
Indices
ETFs

Analysis

Fed
ECB
COT
Economic Calendar

Learn

Service Guide
MCP Server
Oil

Company

About
Contact
Data Methodology
AI Disclosure
Pricing
Enterprise
Terms
Privacy
Security
WhatsApp

Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookiesPrivacy Policy

AI Financial Intelligence
Professional analysis of central bank decisions

Markets

News
Forex
Stocks
Crypto
Gold
Commodities
Indices
ETFs

Analysis

Fed
ECB
COT
Economic Calendar

Learn

Service Guide
MCP Server
Oil

Company

About
Contact
Data Methodology
AI Disclosure
Pricing
Enterprise
Terms
Privacy
Security
WhatsApp

Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

BreakingStocks

Eli Lilly Q3 Revenue Surges 39% as Company Raises Full-Year Guidance

First Detected: Oct 29, 2026, 10:52 AM

Last Update: 22 minutes ago

1 update

Event Summary

Eli Lilly reported a 39% surge in third-quarter revenue to $24.4 billion, primarily driven by strong sales of Mounjaro and Zepbound. The company raised its full-year financial guidance and highlighted significant regulatory progress across its portfolio. Quarterly revenue also included $900 million in specific benefits, including $410 million from Jardiance-related milestones.

Timeline

Latest developmentabout 4 hours ago

Eli Lilly Revenue Jumps 39% to $24.397 Billion in Third Quarter

The company raised its 2026 revenue outlook on stronger demand and volume, while lower realized prices weighed on sales and guidance showed a divergence between revenue and earnings per share.

Read the full story

Key facts

Eli Lilly's Q3 revenue increased 39% to $24.4 billion, driven primarily by sales of Mounjaro and Zepbound.
The company raised its full-year financial guidance and highlighted regulatory progress across its portfolio.
Q3 revenue included $900 million in benefits, including $410 million from Jardiance milestones.

Price Impact

Since event start

LLY+7.43%